The Quick Answer
A GLP-1 titration schedule starts at a low introductory dose and increases in steps over several weeks until you reach a maintenance dose. The point of the slow climb is tolerability: gastrointestinal side effects concentrate during dose escalation, so a low start with gradual increases gives your body time to adjust at each level.2 Standard FDA-labeled schedules use four-week steps,3 but the right pace is individual. Some people need to hold a dose longer; some can move sooner. At Defiant in Lisle, we titrate bi-weekly with weekly nurse check-ins, which gives a provider more frequent decision points to speed up, slow down, or hold based on how you are actually responding.
A GLP-1 titration schedule is the plan for how you start at a low dose and step up gradually until you reach an effective dose your body tolerates. You do not begin a GLP-1 at a full dose. You ramp into it, because climbing slowly is what keeps the side effects manageable and lets your gut adjust at each step.
This post explains how a standard titration schedule works, why the climb is staged the way it is, and why the interval between dose changes matters as much as the doses themselves. It also covers where bi-weekly titration fits, and how a supervised ramp differs from a fixed telehealth calendar.
What Titration Means
Titration is the process of adjusting a medication dose in steps to reach the amount that works for you with the fewest side effects. With GLP-1 medications, it means starting low and increasing on a schedule rather than beginning at a full therapeutic dose.
The reason is mechanical. GLP-1 medications slow how fast your stomach empties, which is part of how they reduce appetite and help you feel full longer. That same slowing is why the common side effects are digestive. Introduce the effect gradually and most people adjust comfortably. Introduce it too fast and the nausea, fullness, and GI upset get loud.
Titration is the main tool for staying comfortable while the medication does its job.
How a Standard GLP-1 Titration Schedule Works
Both of the leading GLP-1 medications follow a staged ramp. The starting dose is well below the effective dose, and you step up at set intervals as long as you are tolerating the current level.
Here is the general shape of the FDA-labeled escalation for the two most common options. These are the reference schedules, not a prescription. Your provider sets your actual plan.
| Stage | Semaglutide (weekly)3 | Tirzepatide (weekly)4 |
|---|---|---|
| Starting dose | 0.25 mg | 2.5 mg |
| Typical step interval | every 4 weeks | every 4 weeks |
| Escalation path | 0.25 → 0.5 → 1 → 1.7 → 2.4 mg | 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg |
| Maintenance range | up to 2.4 mg | up to 15 mg |
Two things to read from this table. First, the introductory dose is a starting point for tolerability, not a treatment dose. Second, the climb is staged on purpose, with weeks between each increase so your body can settle before the next step.
The labeled schedules also build in flexibility. If you reach a step that is hard to tolerate, the guidance is to delay the increase, and in some cases step back down, rather than push ahead on schedule.3
Why the Dose Climbs Slowly
The slow climb exists to manage side effects, and the trial data shows why it works.
Gastrointestinal symptoms cluster during the titration period rather than at a stable maintenance dose.2 In the STEP-1 trial of semaglutide, about 74 percent of participants reported a GI symptom at some point, with nausea the most common, and most events were mild to moderate and concentrated while the dose was being raised.2 In the SURMOUNT-1 trial of tirzepatide, nausea was reported by roughly 25 to 33 percent of participants depending on dose, again mostly mild to moderate and tied to the escalation phase.1
A lower starting dose with gradual increases is designed to reduce that gastrointestinal load, which is the stated reason the labeled titration schedules ramp slowly instead of jumping to an effective dose.3 Pacing the climb to your tolerance, rather than rushing it, can help keep side effects on the comfortable end of the range.
The practical translation: the speed of your ramp is the single biggest lever you have over how you feel.
Starting Dose vs Effective Dose
A common point of confusion is that the starting dose is not meant to drive weight loss. It is meant to introduce the medication gently.
The introductory doses, 0.25 mg for semaglutide and 2.5 mg for tirzepatide, sit below the range where most of the appetite and weight effects show up.34 That is by design. You spend the first few weeks letting your body acclimate, then climb toward a dose that does the work.
This is also why patience early on pays off. People sometimes feel discouraged that the scale has not moved in the first few weeks at a starting dose. That is expected. The starting dose is just the on-ramp. The bigger appetite changes typically arrive as you move up the schedule toward a maintenance dose.
It is worth noting that "effective dose" is individual. Not everyone needs to reach the top of the range. Some people respond well at a middle step and stay there. The goal is the lowest dose that gets you results you can sustain comfortably, not the highest number on the pen.
Bi-Weekly vs Monthly Titration
The labeled schedules use four-week steps, but the interval between dose decisions is a meaningful choice, and not every program handles it the same way.
Many telehealth programs run a rigid monthly step-up: the same calendar for everyone, regardless of how your gut is handling the current dose. The problem shows up when a dose increase lands hard. If you have to wait until the next monthly check-in to adjust, you may spend weeks white-knuckling a dose that was raised too fast or too far.
Bi-weekly titration shortens that feedback loop. Two-week intervals give a provider more frequent decision points to hold a dose, slow the climb, or move ahead based on how you are actually responding, rather than defaulting to a fixed calendar. The dose can track your body instead of the other way around.
| Approach | Decision points | What happens if a dose lands hard |
|---|---|---|
| Monthly titration | Every 4 weeks | You may wait weeks for the next adjustment |
| Bi-weekly titration | Every 2 weeks | A provider can slow or hold the climb sooner |
Bi-weekly titration means checking in more often so the climb can be paced to you. Sometimes that means moving up sooner because you are tolerating things well. Often it means holding steady because your body needs another two weeks. Bi-weekly titration is the differentiator because it makes the schedule responsive.
What Can Change Your Titration Pace
No single schedule fits everyone. Several factors influence how fast or slow your provider moves you up.
Your side-effect response is the biggest one. Strong nausea or GI symptoms at a given step are a signal to hold or slow down rather than push ahead. How you tolerate each dose effectively sets your pace.
Your goals and starting point matter too. Where you land for a maintenance dose depends on your response, your labs, and how sustainable a given dose feels day to day. Some people reach their target at a middle step and never need the top of the range.
Other inputs include your medical history, other medications, and how your appetite and weight are actually trending on body composition tracking. This is the kind of judgment that benefits from a real provider relationship rather than an automated calendar, which is why supervision matters during titration.
None of this is something to self-manage. Dose changes should always run through the provider managing your protocol.
How Defiant Titrates GLP-1s in Lisle
Every medical weight loss protocol at Defiant starts with a provider consult, a lab review, and a Styku 3D body composition scan as your baseline. From there, your dose is titrated bi-weekly with weekly nurse check-ins, so there is a real person to message when a dose increase does not sit right.
That cadence is the point. A titration schedule works best when someone can adjust it quickly, rather than leaving you on a fixed monthly step-up regardless of how your body is responding. We offer both tirzepatide and semaglutide protocols, with the climb built around your labs, your tolerance, and your goals.
We also track more than the number on the scale. Body composition scanning shows whether you are losing fat while holding lean mass, and GLP-1 muscle-preservation training is available as an add-on to protect strength as you move up your schedule.
Defiant is at 5100 Lincoln Ave in Lisle, serving Naperville, Downers Grove, Wheaton, Oak Brook, and Chicago's western suburbs.
- A GLP-1 titration schedule starts at a low introductory dose and steps up gradually toward a maintenance dose, rather than beginning at a full dose.
- The slow climb exists to manage side effects. GI symptoms cluster during dose escalation and ease at a stable dose, so pacing the ramp keeps you comfortable.
- Standard FDA-labeled schedules use four-week steps: semaglutide climbs from 0.25 mg toward 2.4 mg, tirzepatide from 2.5 mg toward 15 mg.
- The starting dose is an on-ramp for tolerability, not a weight-loss dose. The appetite effects typically arrive as you climb the schedule.
- The interval between dose decisions matters. Bi-weekly titration gives a provider more frequent points to slow, hold, or advance than a fixed monthly schedule.
- The right pace is individual and should always be managed by your provider, who adjusts based on your tolerance, labs, and goals.
Common Questions
Paced to You.
Bi-weekly titration and weekly nurse check-ins mean your dose climbs at the speed your body can handle, not a fixed monthly calendar. Book a consultation and start a GLP-1 protocol built around your biology.
Keep Reading
Last updated June 22, 2026.
References
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022. NEJM (SURMOUNT-1)
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1). New England Journal of Medicine. 2021. NEJM (STEP-1)
- U.S. Food and Drug Administration. Wegovy (semaglutide) injection, prescribing information. 2025. FDA label (PDF)
- U.S. Food and Drug Administration. Zepbound (tirzepatide) injection, prescribing information. 2024. FDA label (PDF)